A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours

BACKGROUND: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). PATIENTS AND METHODS: In stage 1, 11 patients received 400 mg BEZ23...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Anticancer Res
Auteurs principaux: FAZIO, NICOLA, BUZZONI, ROBERTO, BAUDIN, ERIC, ANTONUZZO, LORENZO, HUBNER, RICHARD A., LAHNER, HARALD, DE HERDER, WOUTER W., RADERER, MARKUS, TEULÉ, ALEXANDRE, CAPDEVILA, JAUME, LIBUTTI, STEVEN K., KULKE, MATTHEW H., SHAH, MANISHA, DEY, DEBARSHI, TURRI, SABINE, AIMONE, PAOLA, MASSACESI, CRISTIAN, VERSLYPE, CHRIS
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5076549/
https://ncbi.nlm.nih.gov/pubmed/26851029
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires